瑞典卡罗琳斯卡研究所Petter Brodin研究组在儿童实体瘤患者中，进行系统级免疫监测以实现精准医学。相关论文于2025年1月20日在线发表在《细胞》杂志上。

研究人员对191名来自不同肿瘤类型的儿童进行系统级免疫反应分析，揭示了年龄和肿瘤类型在免疫反应中起到不同的作用。系统性炎症和细胞毒性T细胞反应与肿瘤突变率和免疫细胞浸润相关。

在诊断时，扩展克隆的T细胞反应在血液或肿瘤中很少被检测到，但在治疗过程中有时会被激发。在免疫原性较强的癌症中，扩增的T细胞在儿童和成人中都表现出类似的调控方式。该研究旨在促进精准免疫疗法的开发，以帮助癌症儿童的治疗。

据了解，癌症是儿童因病死亡的主要原因。生存率不仅依赖于手术、细胞毒性药物和放疗，还依赖于系统性免疫反应。影响不同年龄段和肿瘤类型儿童免疫反应的因素尚不明确。新的免疫疗法可以增强抗肿瘤免疫反应，但很少有儿童受益，且缺乏有效反应的标志物。

附：英文原文

Title: Systems-level immunomonitoring in children with solid tumors to enable precision medicine

Author: Qi Chen, Binbin Zhao, Ziyang Tan, Gustav Hedberg, Jun Wang, Laura Gonzalez, Constantin Habimana Mugabo, Anette Johnsson, Erika Negrini, Laura Piero Páez, Lucie Rodriguez, Anna James, Yang Chen, Jaromír Mike, Anna Karin Bernhardsson, Stefan Markus Reitzner, Ferdinand von Walden, Olivia O’Neill, Hugo Barcenilla, Chunlin Wang, Mark M. Davis, Lena-Maria Carlson, Niklas Pal, Klas Blomgren, Dirk Repsilber, Nikolas Herold, Tadepally Lakshmikanth, Per Kogner, Linda Ljungblad, Petter Brodin

Issue&Volume: 2025-01-20

Abstract: Cancer is the leading cause of death from disease in children. Survival depends not only on surgery, cytostatic drugs, and radiation but also on systemic immune responses. Factors influencing these immune responses in children of different ages and tumor types are unknown. Novel immunotherapies can enhance anti-tumor immune responses, but few children have benefited, and markers of effective responses are lacking. Here, we present a systems-level analysis of immune responses in 191 children within a population-based cohort with diverse tumors and reveal that age and tumor type shape immune responses differently. Systemic inflammation and cytotoxic T cell responses correlate with tumor mutation rates and immune cell infiltration. Clonally expanded T cell responses are rarely detected in blood or tumors at diagnosis but are sometimes elicited during treatment. Expanded T cells are similarly regulated in children and adults with more immunogenic cancers. This research aims to facilitate the development of precision immunotherapies for children with cancer.

DOI: 10.1016/j.cell.2024.12.014

Source: https://www.cell.com/cell/abstract/S0092-8674(24)01427-2